Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$263.52
$257.42
$186.05
▼
$282.15
$16.44B0.35490,070 shs443,598 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$32.47
$31.00
$23.62
▼
$35.43
$20.25B0.842.17 million shs1.39 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$76.27
$73.34
$35.20
▼
$82.94
$5.95B0.09459,095 shs576,541 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$497.11
$520.91
$396.12
▼
$609.35
$21.32B0.56490,665 shs359,358 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-2.60%+6.04%+18.02%+34.74%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%-3.36%+1.66%+32.10%+16.71%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
0.00%-2.10%-0.63%+45.72%+105.58%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%+1.95%-0.52%-9.55%+22.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$263.52
$257.42
$186.05
▼
$282.15
$16.44B0.35490,070 shs443,598 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$32.47
$31.00
$23.62
▼
$35.43
$20.25B0.842.17 million shs1.39 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$76.27
$73.34
$35.20
▼
$82.94
$5.95B0.09459,095 shs576,541 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$497.11
$520.91
$396.12
▼
$609.35
$21.32B0.56490,665 shs359,358 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-2.60%+6.04%+18.02%+34.74%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%-3.36%+1.66%+32.10%+16.71%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
0.00%-2.10%-0.63%+45.72%+105.58%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%+1.95%-0.52%-9.55%+22.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$310.0017.64% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$39.5021.65% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.80
Moderate Buy$87.3814.56% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.85
Moderate Buy$646.0029.95% Upside

Current Analyst Ratings Breakdown

Latest KNSA, UTHR, GMAB, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$344.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$304.00 ➝ $312.00
9/1/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$275.00 ➝ $273.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$327.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$333.00 ➝ $330.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$328.00 ➝ $326.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$345.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$306.00 ➝ $304.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M20.18N/AN/A($2.97) per share-88.73
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B5.44$1.61 per share20.17$9.10 per share3.57
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$677.56M8.78$0.79 per share96.09$7.44 per share10.25
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B6.70$32.99 per share15.07$164.81 per share3.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8920.4429.58N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2725.5720.421.8319.08%14.89%7.73%11/5/2026 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$59.01M$0.9778.6336.85N/A9.59%13.65%10.09%10/27/2026 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$27.9517.7916.762.4941.56%20.18%17.98%11/4/2026 (Estimated)

Latest KNSA, UTHR, GMAB, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
8/5/2026Q2 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.86$7.27+$0.41$7.27$804.65 million$783.30 million
7/28/2026Q2 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.2995$0.30+$0.0005$0.30$226.49 million$243.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.90
3.49
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
5.73
5.41

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
53.95%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
51.98%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029623.78 million614.17 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
36678.02 million37.47 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.89 million39.20 millionOptionable

Recent News About These Companies

WINTON GROUP Ltd Trims Holdings in United Therapeutics Corporation $UTHR
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-winton-group-ltd-trims-holdings-in-united-therapeutics-corporation-uthr-2026-09-14/
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,772,325.00 in Stock
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31022666
National Pension Service Sells 2,208 Shares of United Therapeutics Corporation $UTHR
September 13 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-national-pension-service-sells-2208-shares-of-united-therapeutics-corporation-uthr-2026-09-13/
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares
September 11 at 5:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-sells-9500-shares-2026-09-11/
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), United Therapeutics (UTHR) and Spyre Therapeutics (SYRE)
September 11 at 2:45 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/UTHR-Q/pressreleases/4538950/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-united-therapeutics-uthr-and-spyre-therapeutics-syre/
United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?
September 10, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/united-therapeutics-uthr-sets-477-6-million-buyback-can-pipeline-funding-keep-pace-1835896/
United Therapeutics Corporation $UTHR Holdings Decreased by Krensavage Asset Management LLC
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-united-therapeutics-corporation-uthr-holdings-decreased-by-krensavage-asset-management-llc-2026-09-10/
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock
September 10, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-09-10/
Amundi Acquires 71,495 Shares of United Therapeutics Corporation $UTHR
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-acquires-71495-shares-of-united-therapeutics-corporation-uthr-2026-09-10/
United Therapeutics : une dirigeante cède des actions pour un montant de 4 740 795 dollars, selon une déclaration à la SEC
September 9, 2026  |  zonebourse.comZ
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/therapeutics-stocks-q2-teardown-united-201038327.html
United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944710-united-therapeutics-corporation-uthr-presents-at-12th-annual-cantor-fitzgerald-global
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-sells-9500-shares-of-stock-2026-09-09/
United Therapeutics enters $477.6M accelerated share repurchase
September 8, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/united-therapeutics-enters-4776m-accelerated-share-repurchase/ar-AA2bO5p0
United Therapeutics Announces New Accelerated Share Repurchase
September 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/united-therapeutics-announces-new-accelerated-share-repurchase?utm_source=marketbeat.com&utm_medium=referral
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-martine-rothblatt-sells-9500-shares-of-united-therapeutics-nasdaq-uthr-stock-2026-09-08/
United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
September 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943946-united-therapeutics-corporation-uthr-presents-at-wells-fargo-21st-annual-healthcare
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
September 8, 2026  |  markets.ft.comhttps://markets.ft.com/data/announce/detail?dockey=600-202609080700BIZWIRE_USPRX____20260908_BW134529-1
California State Teachers Retirement System Grows Stake in United Therapeutics Corporation $UTHR
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-grows-stake-in-united-therapeutics-corporation-uthr-2026-09-08/
Hsbc Holdings PLC Raises Stake in United Therapeutics Corporation $UTHR
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-raises-stake-in-united-therapeutics-corporation-uthr-2026-09-08/
16,970 Shares in United Therapeutics Corporation $UTHR Purchased by Nykredit A S
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-16970-shares-in-united-therapeutics-corporation-uthr-purchased-by-nykredit-a-s-2026-09-06/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$263.52 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$263.90 +0.38 (+0.14%)
As of 07:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$32.47 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$32.46 -0.01 (-0.02%)
As of 06:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$76.27 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$75.90 -0.37 (-0.49%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$497.11 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$499.75 +2.64 (+0.53%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas